No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer
Mené sur 645 patients atteints d'un cancer métastatique de l'estomac ou de la jonction œsogastrique, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du ramucirumab à une chimiothérapie de première ligne combinant cisplatine et fluoropyrimidine
In this century, anti-angiogenic therapy has played a part in the treatment of multiple solid cancers. Possible strategies to inhibit the angiogenic VEGF–VEGFR signalling axis include targeted therapy against VEGF ligand, VEGFR-2, and VEGFR tyrosine kinases. These approaches have identified ramucirumab, a recombinant, fully human IgG1 monoclonal antibody specific for VEGFR-2, as the most successful anti-angiogenic compound in gastric cancer treatment. This finding has led to approval by the US Food and Drug Administration and European Medicines Agency of ramucirumab (in combination with paclitaxel or as monotherapy) for second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with disease progression after previous platinum and fluoropyrimidine chemotherapy.
The Lancet Oncology , commentaire, 2018